GlaxoSmithKline Pharmaceuticals today reported a 27.45 per cent rise in its standalone net profit at Rs 128.67 crore for the third quarter ended September.
The company had posted a net profit of Rs 100.95 crore for the corresponding period of the previous fiscal, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.
The standalone total income from operations also rose to Rs 746.76 crore for the quarter under consideration from Rs 626.65 crore for the same period year-ago, it added.
The company follows the January-December financial year.
Established in 1924 in India, GlaxoSmithKline Pharmaceuticals’ product portfolio includes prescription medicines and vaccines.
The company’s prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases.